Perspective Therapeutics (NYSEAMERICAN:CATX) Stock: Insider Markus Puhlmann Purchases 35,000 Shares

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) insider Markus Puhlmann acquired 35,000 shares of the stock in a transaction dated Thursday, November 12th. The stock was bought at an average cost of $0.84 per share, with a total value of $29,400.00. Following the completion of the purchase, the insider owned 178,542 shares of the company’s stock, valued at approximately $149,975.28. The trade was a 24.38% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Markus Puhlmann also recently made the following trade(s):

• On Wednesday, November 11th, Markus Puhlmann bought 6,000 shares of Perspective Therapeutics stock. The stock was bought at an average price of $0.83 per share, for a total transaction of $4,980.00.

Perspective Therapeutics Price Performance

Shares of NYSEAMERICAN:CATX traded up $0.10 during mid-day trading on Friday, hitting $0.94. 3,183,208 shares of the company traded hands, compared to its average volume of 4,328,272. The company has a quick ratio of 6.61, a current ratio of 5.18 and a debt-to-equity ratio of 0.01. Perspective Therapeutics, Inc. has a 12-month low of $0.78 and a 12-month high of $6.16. The stock has a 50-day moving average price of $2.11 and a two-hundred day moving average price of $3.44.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.06 million. Perspective Therapeutics had a negative return on equity of 42.25% and a negative net margin of 55,866.82%. On average, equities research analysts expect that Perspective Therapeutics, Inc. will post -1.01 EPS for the current year.

Institutional Trading of Perspective Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP bought a new position in shares of Perspective Therapeutics during the 3rd quarter valued at approximately $4,075,000. Empowered Funds LLC purchased a new stake in Perspective Therapeutics in the 3rd quarter worth about $338,000. Nantahala Capital Management LLC increased its holdings in Perspective Therapeutics by 7.2% in the 3rd quarter. Nantahala Capital Management LLC now owns 2,492,642 shares of the company’s stock worth $6,855,000 after acquiring an additional 167,192 shares during the last quarter. Voya Investment Management LLC raised its stake in Perspective Therapeutics by 34.4% in the 3rd quarter. Voya Investment Management LLC now owns 453,650 shares of the company’s stock valued at $1,248,000 after acquiring an additional 116,149 shares during the period. Finally, Russell Investments Group Ltd. raised its stake in Perspective Therapeutics by 53.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 61,012 shares of the company’s stock valued at $168,000 after acquiring an additional 21,150 shares during the period. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. BMO Capital Markets reiterated an “outperform” rating on shares of Perspective Therapeutics in a research note on Friday, October 30th. Bank of America dropped their price target on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Friday, August 14th. William Blair assumed coverage on shares of Perspective Therapeutics in a report on Friday, September 18th. They set an “outperform” rating on the stock. Royal Bank Of Canada cut shares of Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and cut their price target for the stock from $14.00 to $4.00 in a report on Monday, October 26th. Finally, BTIG Research reaffirmed a “buy” rating on shares of Perspective Therapeutics in a report on Monday, October 26th. Nine investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $10.10.

Top Perspective Therapeutics Stories

Here are a few of the latest stories about CATX:

• Positive Sentiment: BMO Capital gave CATX a Buy rating, adding a bullish analyst view. BMO Capital rating
• Neutral Sentiment: Brookline Capital Markets made slightly different revisions to its earnings forecasts: it raised its Q4 2026 estimate to a loss of $0.25 per share from $0.26, but lowered its full-year estimate to a loss of $1.00 from $0.99. Perspective Therapeutics analyst estimates
• Negative Sentiment: The company’s latest reported quarter missed expectations: its loss of $0.27 per share was wider than the $0.24 consensus estimate, while revenue of $0.02 million fell short of the $0.06 million forecast. This weak operating performance may weigh on sentiment. CATX earnings information

About Perspective Therapeutics

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.